http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
-
Orchard Therapeutics Announces New England Journal of Medicine Publication of Interim Proof-of-concept Study Results of OTL-203 for Hurler Syndrome
-
Aruvant Appoints Moya Daniels as Senior Vice President of Regulatory Affairs and Quality Assurance
-
Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021
-
Orchard Therapeutics to Present at Virtual Investor Conferences in November 2021
-
Cryoport Reports Record Third Quarter and Nine Months Revenue for 2021
-
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
-
Orchard Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Updates
-
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
-
Orchard Therapeutics Outlines Comprehensive Presence at the European Society of Gene & Cell Therapy Congress
-
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
-
Orchard Therapeutics Outlines Differentiated Profile of Its HSC Gene Therapy Approach and Discusses Potential Future Applications at Virtual R&D Investor Event
-
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
-
Orchard Therapeutics Bolsters R&D and Technical Operations Leadership with New Executive Appointments
-
Orchard Therapeutics to Host Virtual R&D Investor Event on Tuesday, September 14, 2021
-
Orchard Therapeutics to Host Virtual R&D Investor Event on Tuesday, September 14, 2021
-
Orchard Therapeutics Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Orchard Therapeutics Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
-
Orchard Therapeutics to Present at Multiple Investor Conferences in September 2021
-
Orchard Therapeutics to Present at Multiple Investor Conferences in September 2021
-
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
-
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates
-
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
-
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema
-
Orchard Therapeutics (ORTX) Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
-
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
-
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs
-
G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
-
Cryoport Expands Global Supply Chain Network with Belgium Acquisition
-
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
-
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates
-
Orchard Therapeutics Plc (ORTX) Reports Publication of HSC Gene Therapy Data for ADA-SCID
-
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
-
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID
-
Albireo Reports Q1 Financial Results and Business Update
-
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
-
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy
-
Be The Match BioTherapies® Announces Expansion of Multi-Year Strategic Alliance with Orchard Therapeutics to Support European Commercial Launch of Libmeldy™
-
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
-
Orchard Therapeutics Reports 2020 Financial Results and Reviews Recent Accomplishments
-
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
-
Orchard Therapeutics to Present at Multiple Investor Conferences in March 2021
-
Orchard Therapeutics (ORTX) Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome
-
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
-
Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH)
-
Orchard Therapeutics Plc (ORTX) Reports $150M Strategic PIPE Financing from 24.12M Share Sale at $6.22/Sh
-
Orchard Therapeutics Announces $150 Million Strategic Financing
-
Orchard Therapeutics Announces $150 Million Strategic Financing
-
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
-
Orchard Therapeutics Appoints Braden Parker as Chief Commercial Officer
